# Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors

> **NCT07086768** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Lei Zheng** · enrollment: 57 (estimated)

## Conditions studied

- Solid Tumor
- Advanced Solid Tumor
- Metastatic Solid Tumor

## Interventions

- **DRUG:** BSI-082
- **OTHER:** Trastuzumab deruxtecan

## Key facts

- **NCT ID:** NCT07086768
- **Lead sponsor:** Lei Zheng
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01-01
- **Primary completion:** 2027-08-07
- **Final completion:** 2028-08-07
- **Target enrollment:** 57 (ESTIMATED)
- **Last updated:** 2025-09-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07086768

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07086768, "Dose-Escalation and Dose-Expansion Study of BSI-082 Monotherapy and Combined Therapy in Patients With Advanced or Metastatic Solid Tumors". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT07086768. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*